FILTER

Refine your search with the following facets to narrow down your results.

5 Current news of Innate Pharma

Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement for an Investigational Immuno-Oncology Biologic

08-Jul-2011 - Bristol-Myers Squibb Company and Innate Pharma S.A. announced a global agreement for the development and commercialization of IPH2102, a novel antibody in Phase I development for the treatment of cancer.Under the terms of the agreement, Innate Pharma will grant to Bristol-Myers Squibb exclusive ...

Bristol-Myers Squibb cancer cooperations

Initiation of a Phase II clinical trial with anti-KIR monoclonal antibody IPH 2101 in smoldering myeloma patients

25-Nov-2010 - Innate Pharma announced that it has started patient inclusion in a new multicenter Phase II clinical trial with IPH 2101, an anti-KIR monoclonal antibody potentiating the anti-tumor activity of NK cells. In this trial, IPH 2101 is tested as a single agent in patients with smoldering myeloma, an ...

clinical trials medicine multiple myeloma +2

Innate Pharma initiates collaboration with Celgene to evaluate the clinical potential of REVLIMID combined with IPH 2101

19-Nov-2009 - Innate Pharma announced that Celgene Corporationhas agreed to collaborate with Innate Pharma to evaluate the potential clinical synergy of the combination treatment regimen of lenalidomide (REVLIMID®) plus IPH 2101 in patients with multiple myeloma (“MMy”) who have failed first-line therapy. The ...

Celgene clinical trials lenalidomide +2

Innate Pharma reports phase II clinical data with IPH 1101 in oncology

21-Sep-2009 - Innate Pharma reports interim data from the Phase I/II clinical trial evaluating IPH 1101 in combination with rituximab1 in follicular non-Hodgkin’s lymphoma (“fNHL”) patients (study “IPH 1101-202”) and final data for the Phase IIa trial evaluating IPH 1101 in chronic myeloid leukemia (“CML”) ...

chronic myeloid leukemia clinical trials cytokines +2

Inserm Transfert and Innate Pharma enter into a partnership for the development of antibodies for the treatment of cancer

14-Sep-2009 - Inserm Transfert and Innate Pharma announce the execution of an agreement facilitating the development of antibodies in cancer, inflammation and auto-immunity. This partnership of a new kind will enable Innate Pharma to be informed of the discovery of promising antibody targets at an early stage, ...

antibodies immunity inflammation +1